HomeCommentary

Commentary

Will NHI Pricing Reform in Sluggish Domestic Market Trigger Industry Reorganization?
(Feb.6.2017)

By Reiji Anasako

Drug makers have begun announcing their financial results for April-December 2016. In the domestic ethical drug market, major products and continued launches of new drugs supported growth, while sales by companies that mainly depend on long-listed products inevitably declined compared to the same period of the previous year. Some companies that have a number of new products also struggled, and their future prospects remain in doubt. To what extent does the reform of the NHI pricing system that was hurriedly decided on at the end of last year factor in the current state of the pharmaceutical industry? ...

(LOG IN FOR FULL STORY)

News Calendar